Evotec's business model is transitioning from a traditional discovery services provider toward a capital-efficient biologics CDMO and technology licensing firm, supported by proprietary continuous manufacturing and molecular patient data assets. While the discovery segment faces cyclical headwinds …
Evotec SE (EWTX) H1 2025: 16% Growth in Just – Evotec Biologics Offsets Discovery Segment Softness
Evotec's strategic pivot toward biologics manufacturing gains traction with strong segment growth despite ongoing headwinds in discovery services. The planned sale of the Toulouse biologics site marks a key step in capital efficiency and revenue mix enhancement. Investors should watch for the impact of evolving biotech funding and the integration of AI-driven platforms on future growth.
Summary
- Biologics Segment Expansion: Just – Evotec Biologics is driving robust growth and shaping a capital-light CDMO model.
- Discovery Segment Challenges: Discovery & Preclinical Development faces continued softness amid cautious early-stage biotech funding.
- Strategic Transition: Asset-light approach and technology licensing underpin midterm revenue and margin targets.
Business Overview
Evotec SE is a drug discovery and development company structured into two core segments: Discovery and Preclinical Development (D&PD), focused on small molecule and novel modality research from target identification to Investigational New Drug (IND) stage; and Just – Evotec Biologics (JEP), which provides large molecule biologics process development and manufacturing services. The company generates revenue through service fees, technology licensing, milestones, and royalties linked to partner drug development programs.
Performance Analysis
In the first half of 2025, Evotec reported group revenues of €371.2 million, down 5% year-over-year, reflecting a mixed performance between its segments. The D&PD segment experienced an 11% revenue decline to €269 million, primarily due to subdued demand from early-stage biotech clients and a temporary dip in Bristol Myers Squibb (BMS) collaboration revenues. Excluding BMS effects, the underlying decline in D&PD was a normalized 6%, signaling persistent headwinds in the discovery services market.
Conversely, Just – Evotec Biologics delivered a strong 16% revenue increase to €102.2 million, driven by growth in non-Sandoz and Department of Defense (DoD) customers. This segment’s gross margin improved slightly to 9.1%, supported by a favorable revenue mix and operational leverage despite ongoing investments in organizational build-out. Adjusted Group EBITDA was a negative €1.9 million, with JEP’s positive contribution of €7.5 million offsetting softness in D&PD.
- Revenue Mix Shift: The contrasting segment trends highlight Evotec's evolving revenue composition toward higher-margin biologics services.
- Cost Discipline: R&D expenses fell 35% to €19 million, reflecting focused capital allocation, while SG&A costs declined modestly, underscoring operational efficiency.
- Cash Flow Improvement: Operating cash flow improved significantly, benefiting from lower net losses and working capital management, supporting liquidity of €348 million.
Overall, the financials reveal a company navigating legacy discovery market softness while capitalizing on growth and margin expansion in biologics manufacturing, positioning itself for improved profitability and capital efficiency.
Executive Commentary
"Just Evotec Biologics remains on a strong growth path, driven by our unrelenting focus on technology leadership and biologics."
Dr. Christian Wojcicki, CEO
"We have now reached an FTE reduction of 600 since March 2024, which is 200 FTE above the original priority reset target, and we've already realized about 50% of our updated cost out target of €30 million."
Paul Hitchen, CFO
Strategic Positioning
1. Transition to Asset-Light Biologics Model
Evotec is actively pivoting Just – Evotec Biologics toward a capital-efficient, asset-light model, exemplified by the planned sale of the Toulouse J-POD manufacturing facility to Sandoz. This transaction, expected to close in Q4 2025, will transfer the asset while Evotec retains core intellectual property and technology licensing rights. The move aligns with the company’s strategy to leverage proprietary continuous manufacturing technology via partnerships, enhancing revenue mix and profitability.
2. Strengthening Discovery & Preclinical Development Focus
Despite current market softness, Evotec is reinforcing its discovery segment by investing in technology platforms such as the molecular patient database, now expanded to over 27,000 patients across multiple therapeutic areas including kidney disease, immunology, and metabolic disorders. This data-driven approach aims to deepen target identification and validation capabilities, creating higher-value integrated partnerships beyond traditional contract research organization (CRO) services.
3. Leveraging AI and Omics for Drug Discovery Innovation
Evotec is integrating artificial intelligence (AI) and machine learning tools into its drug discovery processes, particularly in early target identification and drug design. The company’s omics-based platforms, supported by proprietary assay systems, position it to capitalize on the FDA’s increasing emphasis on computational modeling, enhancing predictive accuracy and accelerating development timelines.
4. Operational Excellence and Cost Optimization
Since 2024, Evotec has undertaken significant organizational adjustments, including workforce reductions exceeding initial targets and stringent external spend controls. These measures have improved operational leverage and are expected to contribute further productivity gains, supporting the company’s midterm goal of achieving above 20% adjusted EBITDA margin by 2028.
5. Expanding Customer Base and Revenue Streams
Just – Evotec Biologics’ growth is fueled by broadening its customer portfolio beyond Sandoz and DoD to include multiple large pharmaceutical companies and biotech firms. The company is evolving its commercial model to offer standalone services, integrated drug discovery, and strategic partnerships, enabling diversified revenue streams including development fees, technology licenses, milestones, and royalties.
Key Considerations
Evotec’s H1 2025 results underscore its ongoing transformation amid challenging early-stage biotech funding and evolving industry dynamics.
- Funding Environment Impact: Early-stage biotech funding remains cautious, limiting discovery segment demand, but signs of recovery are anticipated in coming quarters.
- Strategic Asset Monetization: The J-POD Toulouse sale reflects a broader shift to monetize capital-intensive assets while retaining technology leadership and recurring revenue potential.
- Technology Differentiation: Proprietary continuous manufacturing and molecular patient data platforms provide competitive moats and growth avenues.
- Cost Reduction Trajectory: Continued execution on cost-out programs supports margin improvement despite revenue pressures.
- Geographic Market Variability: Growth is concentrated in US and European markets, with Asian markets showing more traction but limited exposure currently.
Risks
Evotec faces risks from persistent softness in early-stage discovery funding, potential delays or regulatory hurdles in the Sandoz asset sale, and competitive pressures in both biologics manufacturing and discovery services. Currency fluctuations and macroeconomic uncertainties also pose challenges to financial performance and guidance execution.
Forward Outlook
For H2 2025, Evotec expects Discovery & Preclinical Development revenues to continue at levels similar to H1, reflecting ongoing market softness. Just – Evotec Biologics is anticipated to accelerate growth significantly in the second half, driven by expanded customer engagements and operational leverage.
- Group revenues guidance revised to €760 million to €800 million (previously €840 million to €880 million).
- R&D expenditure expected between €40 million and €50 million, reflecting focused investment.
- Adjusted Group EBITDA forecast maintained at €30 million to €50 million, supported by cost discipline and revenue mix improvements.
Management highlights that foreign exchange headwinds in H2 will be offset by improved business mix and cost savings, underpinning confidence in achieving midterm targets of 8% to 12% revenue CAGR and >20% EBITDA margin by 2028.
Takeaways
Evotec is executing a clear strategic reset, balancing near-term market challenges with investments in high-growth biologics and data-driven discovery platforms.
- Segment Divergence: The contrasting performance between D&PD and JEP segments reflects shifting industry funding patterns and Evotec’s successful repositioning toward biologics manufacturing.
- Capital Efficiency Drive: The J-POD Toulouse sale exemplifies the company’s move to asset-light models, unlocking capital and enhancing margins without sacrificing technology control.
- Technology and Data as Growth Engines: Expansion of molecular patient databases and AI integration strengthens Evotec’s value proposition in precision medicine and integrated drug discovery.
Conclusion
Evotec’s H1 2025 results demonstrate progress in transforming its business model, with Just – Evotec Biologics leading growth and margin expansion while Discovery & Preclinical Development navigates a challenging funding environment. The strategic initiatives underway, including asset monetization and technology platform expansion, position the company for sustainable, profitable growth aligned with its 2028 ambitions.
Industry Read-Through
Evotec’s experience highlights broader biopharma industry trends including cautious early-stage biotech funding, increasing importance of integrated technology platforms, and a shift toward capital-efficient biologics manufacturing models. The company’s asset-light pivot and emphasis on proprietary continuous manufacturing technology may serve as a blueprint for other Contract Development and Manufacturing Organizations (CDMOs) seeking margin expansion and scalability. Additionally, the growing role of omics data and AI in drug discovery underscores a sector-wide move toward precision medicine enabled by advanced computational tools.